Tara Biagi
Overview
Explore the profile of Tara Biagi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1612
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peterson J, Pepin A, Thomas R, Biagi T, Stark E, Sparks A, et al.
J Genet Couns
. 2020 Mar;
29(4):587-593.
PMID: 32196827
For poorly understood reasons, Black non-Hispanic (BNH) women meeting National Comprehensive Cancer Network (NCCN) criteria for genetic testing for breast cancer risk are less likely than White non-Hispanic (WNH) women...
2.
Casasanta N, Kipnis S, Linville L, Lipinski S, Knoedler A, Marino A, et al.
Clin Breast Cancer
. 2019 Sep;
20(2):125-130.
PMID: 31526714
Background: Oncotype DX (ODX) is a genomic assay of tumor tissue that is utilized to predict the likelihood of recurrence and benefit of chemotherapy in breast cancer patients. Five to...
3.
Frost A, Toaff M, Biagi T, Stark E, McHenry A, Kaltman R
Obstet Gynecol
. 2018 May;
131(6):1103-1110.
PMID: 29742654
Objective: To evaluate the role of screening patients at increased risk for hereditary cancer syndromes with an extended panel of cancer predisposition genes to identify actionable genetic mutations. Methods: A...
4.
Casasanta N, Stark E, McHenry A, Biagi T, Kaltman R
Oncologist
. 2018 Feb;
23(4):393-396.
PMID: 29445031
Key Points: With single-site genetic testing, there is the potential to miss hereditary genetic syndromes that can be managed clinically.Between 4% and 6% of hereditary breast and ovarian cancer syndromes...
5.
Marks D, McHenry A, Biagi T, Stark E, Borum M, Lin P, et al.
J Oncol Pract
. 2017 Feb;
13(4):279-281.
PMID: 28195815
No abstract available.
6.
Tonomura N, Elvers I, Thomas R, Megquier K, Turner-Maier J, Howald C, et al.
PLoS Genet
. 2015 Feb;
11(2):e1004922.
PMID: 25642983
Dogs, with their breed-determined limited genetic background, are great models of human disease including cancer. Canine B-cell lymphoma and hemangiosarcoma are both malignancies of the hematologic system that are clinically...
7.
Karlsson E, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, et al.
Genome Biol
. 2013 Dec;
14(12):R132.
PMID: 24330828
Background: Canine osteosarcoma is clinically nearly identical to the human disease, but is common and highly heritable, making genetic dissection feasible. Results: Through genome-wide association analyses in three breeds (greyhounds,...
8.
Grabherr M, Pontiller J, Mauceli E, Ernst W, Baumann M, Biagi T, et al.
PLoS One
. 2011 Jun;
6(5):e20136.
PMID: 21625601
The choice of promoter is a critical step in optimizing the efficiency and stability of recombinant protein production in mammalian cell lines. Artificial promoters that provide stable expression across cell...
9.
Wilbe M, Jokinen P, Truve K, Seppala E, Karlsson E, Biagi T, et al.
Nat Genet
. 2010 Jan;
42(3):250-4.
PMID: 20101241
The unique canine breed structure makes dogs an excellent model for studying genetic diseases. Within a dog breed, linkage disequilibrium is extensive, enabling genome-wide association (GWA) with only around 15,000...
10.
Rivera P, Melin M, Biagi T, Fall T, Haggstrom J, Lindblad-Toh K, et al.
Cancer Res
. 2009 Nov;
69(22):8770-4.
PMID: 19887619
Breast cancer is a major contributor to overall morbidity and mortality in women. Several genes predisposing to breast cancer have been identified, but the majority of risk factors remain unknown....